Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus
Open Access
- 25 October 2023
- journal article
- research article
- Published by Wiley in Health Science Reports
- Vol. 6 (10) , e1648
Abstract
Introduction: Respiratory syncytial virus (RSV), an RNA virus of the family Paramyxoviridae, is the most common cause of respiratory tract diseases, including upper and lower respiratory tract infections in adults. Researchers worldwide have been working for decades to develop an RSV vaccine that is both safe and cost‐effective.Aim: This correspondence aims to highlight the recent breakthroughs in the immunization against RSV for older adults (60 years and above), encompassing the newly sanctioned prophylactic agent by the FDA, drawing attention to its side effects that need to be taken care of and providing clear recommendations to maximize the potential influence of these advancements on RSV‐related diseases globally.Methodology: We did a literature search on RSV among older adults and its treatment on PubMed, Google Scholar, ResearchGate and FDA databases within 10 years. Keywords used for our search were; “Respiratory Syncytial Virus,” “Older adults,” “FDA,” “Arexvy,” and “Immunization.”Result: We found approximately 6000–10,000 lives and 60,000–160,000 hospital admissions among adults aged 65 years and older each year in the world, especially in the United States of America. Currently, there is no vaccine or targeted treatment for RSV for the most affected individuals, that is, the older adults, who are given supportive care. Recently, the USA‐ Food and Drug Administration (FDA) approved Arexvy (a recombinant subunit RSV vaccine) based on its encouraging results demonstrating acceptable safety and efficacy in a large‐scale multi‐centered Phase 3 trial.Conclusion: Authorization of Arexvy, although a breakthrough in the field of research, needs to be approached with a blend of optimism tempered by caution. Robust studies, including large‐scale randomized controlled trials, prospective cohort studies and systematic reviews and meta‐analyses, need to be conducted to ascertain its safety and efficacy.Keywords
This publication has 6 references indexed in Scilit:
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical TrialThe Journal of Infectious Diseases, 2022
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018JAMA Network Open, 2022
- Immunopathology of RSV: An Updated ReviewViruses, 2021
- Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human seraScience Translational Medicine, 2015
- Palivizumab for the prevention of respiratory syncytial virus infection.2010